Literature DB >> 9578550

Photo-cross-linking studies suggest a model for the architecture of an active human immunodeficiency virus type 1 integrase-DNA complex.

T S Heuer1, P O Brown.   

Abstract

The virally encoded integrase protein carries out retroviral integration, which requires specific interactions with the two ends of the viral DNA, and also with host DNA that is the target of integration. We attached a photo-cross-linking agent to specific viral and target DNA sites to identify regions of the integrase polypeptide that are in close proximity to those substrate features in the active integrase-DNA complex. The active form of integrase is a multimer. The higher-order organization of the active integration complex was therefore investigated by determining whether specific cross-links occurred to the active-site containing protomer. Both viral and target DNA cross-links to human immunodeficiency virus type 1 (HIV-1) integrase mapped predominantly to integrase protomers in trans to the active site, in a multimeric integrase complex. The results provide the basis for a model of the protein-DNA architecture of an active HIV-1 integration complex that suggests specific functions for the N-terminal, core, and C-terminal domains of retroviral integrase. One implication of this model is that the integrase multimer that mediates concerted integration of the viral DNA ends is composed of at least eight integrase protomers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9578550     DOI: 10.1021/bi972949c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  67 in total

Review 1.  Retroviral DNA integration.

Authors:  P Hindmarsh; J Leis
Journal:  Microbiol Mol Biol Rev       Date:  1999-12       Impact factor: 11.056

2.  DNase protection analysis of retrovirus integrase at the viral DNA ends for full-site integration in vitro.

Authors:  A Vora; D P Grandgenett
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding.

Authors:  J C Chen; J Krucinski; L J Miercke; J S Finer-Moore; A H Tang; A D Leavitt; R M Stroud
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 integrase: arrangement of protein domains in active cDNA complexes.

Authors:  K Gao; S L Butler; F Bushman
Journal:  EMBO J       Date:  2001-07-02       Impact factor: 11.598

5.  Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein.

Authors:  J Y Wang; H Ling; W Yang; R Craigie
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

6.  Molecular dynamics studies on the HIV-1 integrase catalytic domain.

Authors:  R D Lins; J M Briggs; T P Straatsma; H A Carlson; J Greenwald; S Choe; J A McCammon
Journal:  Biophys J       Date:  1999-06       Impact factor: 4.033

7.  An amino acid in the central catalytic domain of three retroviral integrases that affects target site selection in nonviral DNA.

Authors:  Amy L Harper; Malgorzata Sudol; Michael Katzman
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

8.  Differential multimerization of Moloney murine leukemia virus integrase purified under nondenaturing conditions.

Authors:  Rodrigo A Villanueva; Colleen B Jonsson; Jennifer Jones; Millie M Georgiadis; Monica J Roth
Journal:  Virology       Date:  2003-11-10       Impact factor: 3.616

9.  A quantum mechanic/molecular mechanic study of the wild-type and N155S mutant HIV-1 integrase complexed with diketo acid.

Authors:  Cláudio Nahum Alves; Sergio Martí; Raquel Castillo; Juan Andrés; Vicent Moliner; Iñaki Tuñón; Estanislao Silla
Journal:  Biophys J       Date:  2007-11-02       Impact factor: 4.033

10.  Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.

Authors:  Rajeshri G Karki; Yun Tang; Terrence R Burke; Marc C Nicklaus
Journal:  J Comput Aided Mol Des       Date:  2005-06-27       Impact factor: 3.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.